ArticleBlood2017
Activation of the
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- A systematic review of recent trends in research on therapeutically significant L-asparaginase and acute lymphoblastic leukemia.Molecular biology reports · 2022Pooled it
- Prime Editing, CRISPR-Cas9, and NanoCas Genome Editing for Cancer Treatment.Molecular biotechnology · 2026Review
- Mechanisms of enhancer-driven oncogene activation.International journal of cancer · 2026Review
- Review
- Review
- Article
- Developmental origins shape the paediatric cancer genome.Nature reviews. Cancer · 2024Review
- Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.Leukemia · 2024Article
- ToTAL1y degraded - rapid dTAG proteolysis of TAL1 in T-cell acute lymphoblastic leukemia.Haematologica · 2024Article
- Transcription Factor MYB as Therapeutic Target: Current Developments.International journal of molecular sciences · 2024Review
- Article
- Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy.Molecular cancer · 2024Review
- ETS1 Function in Leukemia and Lymphoma.Advances in experimental medicine and biology · 2024Review
- Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress.Blood · 2023Article
- LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1.Cell death & disease · 2023Article
- RUNX1 colludes with NOTCH1 to reprogram chromatin in T cell acute lymphoblastic leukemia.iScience · 2023Article
- Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition.The Journal of experimental medicine · 2023Article
- TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.Haematologica · 2023Article
- Article
- SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.Clinical lymphoma, myeloma & leukemia · 2022Review
Corrections and comments
- Commented on by
Authors and funding
22 authors at 6 institutions in 3 countries.
Sunniyat RahmanDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Michael MagnussenDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Theresa E LeónDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Nadine FarahDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Zhaodong LiDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Brian J AbrahamWhitehead Institute for Biomedical Research, Cambridge, MA.
Krisztina Z AlapiDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Rachel J MitchellDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Tom NaughtonDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Adele K FieldingDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Arnold PizzeyDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Sophia BustraanDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Christopher AllenDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Teodora PopaDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Karin Pike-OverzetDepartment of Immunohematology, Leiden University Medical Center, Leiden, The Netherlands.
Laura Garcia-PerezDepartment of Immunohematology, Leiden University Medical Center, Leiden, The Netherlands.
Rosemary E GaleDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
David C LinchDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
Frank J T StaalDepartment of Immunohematology, Leiden University Medical Center, Leiden, The Netherlands.
Richard A YoungWhitehead Institute for Biomedical Research, Cambridge, MA.
A Thomas LookDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Marc R MansourDepartment of Haematology, University College London Cancer Institute, London, United Kingdom.
University College London · GBLondon Cancer · GBLeiden University Medical Center · NLDana-Farber Cancer Institute · USMassachusetts Institute of Technology · USWhitehead Institute for Biomedical Research · US
Funding
Zebrafish Screens for Genetic Modifiers and Human Application in T-ALLP01CA068484 · NCI · DANA-FARBER CANCER INSTITUTE · PI KUTOK, JEFFERY LORNE · 1995 to 2010
$31.9MThe Molecular Function of D-cyclins in T-ALLP01CA109901 · NCI · DANA-FARBER CANCER INSTITUTE · PI YOUNG, RICHARD · 2004 to 2014
$19.6MMechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in CancerR35CA210064 · NCI · DANA-FARBER CANCER INST · PI LOOK, A. THOMAS · 2016 to 2022
$7.3MDiscovery of New Targets and Pathways for T-ALL TherapyR01CA176746 · NCI · DANA-FARBER CANCER INST · PI LOOK, A. THOMAS · 2012 to 2015
$1.5MCancer Research UK 21019Cancer Research UK 9609NCI NIH HHS P01 CA068484NCI NIH HHS P01 CA109901NCI NIH HHS R01 CA176746NCI NIH HHS R35 CA210064
Abstract
Somatic mutations within noncoding genomic regions that aberrantly activate oncogenes have remained poorly characterized. Here we describe recurrent activating intronic mutations of
Indexed as
MutationResponse ElementsAdaptor Proteins, Signal TransducingAdolescentAdultChildChild, PreschoolFemaleGene Expression Regulation, LeukemicHumansJurkat CellsLIM Domain ProteinsMalePrecursor T-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene ProteinsAdaptor Proteins, Signal TransducingLIM Domain ProteinsLMO2 protein, humanProto-Oncogene Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.